Table 1.
Clinical characteristics of ATTR patients seen at the Amyloid Program of Calgary from 2014 to 2021
| Characteristic | ALL patients n = 255 |
ATTR patients n = 152 |
AL amyloidosis patients n = 103 |
Pvalue | |
|---|---|---|---|---|---|
| Median age (years, range) | 77 (40–97) | 82 (57–97) | 66 (40–82) | < 0.001 | |
| Gender, n (%) | < 0.001 | ||||
| Female | 64 (25.1%) | 19 (12.5%) | 45 (43.6%) | ||
| Male | 191 (74.9%) | 133 (87.5%) | 58 (56.3%) | ||
| 142 (93.4%) | Localized AL | ||||
| 16 (15.5%) | |||||
| 10 (6.6%) | Systemic AL | ||||
| 87 (84.4%) | |||||
| Median hemoglobin, range (g/L) | 133 (76–173) | 137 (76–172) | 126 (85–173) | 0.3 | |
| Median calcium, mmol/L | 2.34 (1.9–3.5) | 2.35 (1.9–3) | 2.32 (1.96–3.5) | 0.03 | |
| Median creatinine, μmol/L Median | 99 (48–671) | 100 (48–364) | 81 (48–671) | 0.04 | |
| Median eGFR (mL/min/1.73m2) | 59.5 (6–117) | 58 (12–100) | 64 (6–117) | 0.2 | |
| Median albumin, g/L | 33 (7–46) | 35 (7–46) | 29 (8–45) | < 0.001 | |
| Median LDH (U/L) | 221 (48–770) | 223 (60–549) | 205 (48–770) | 0.2 | |
| Median NTproBNP (ng/L) (0–300) | 2462 (40–62,951) | 2960 (40–40,650) | 1185 (50–62,951) | 0.3 | |
| Median hsTroponin T (0–13 ng/L) | 44 (13–357) | 49 (9–357) | 43 (13–337) | 0.04 | |
| Organ Involvement | |||||
| Heart | 207 (81.1%) | 146 (96.1%) | 61/103 (59.2%) | < 0.001 | |
| Kidney | 63 (24.7%) | 0 |
61/87 (70.1%) for Systemic AL only |
< 0.001 | |
| Nerve | 67 (26.2%) | 53 (34.9%) | 63/103 (61.1%) | < 0.001 | |
| Bladder | 4 (1.5%) | 2 (1.3%) | 0.3 | ||
| Gastrointestinal | 22 (8.6%) | 4 (2.6%) | 14/103 (13.5%) | < 0.001 | |
| 2 (1.9%) | |||||
| 18/103 (17.4%) | |||||
Abbreviations: eGFR, estimated glomerular filtration rate = hemoglobin; BMPC, bone marrow plasma cells; NTproBNP, N-terminal pro-b type natriuretic peptide